Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas.

Abstract

Simple SummaryGliomas represent a wide group of central nervous system neoplasms, arising from the glial component of the central nervous system. They are generally sub-classified into astrocytomas, oligodendrogliomas, ependymomas and other rarer subtypes. Apart from morphological and molecular features, there are currently no specific markers for this heterogeneous group of tumors: thus, there is a need to identify more specific and useful markers to distinguish each histological subtype from the others. SRSF1 has been recently characterized as being functionally involved in gliomagenesis and it has been found that SRSF1 is increased in glioma tissues and its increased immunohistochemical expression among adult diffuse astrocytomas is positively correlated with histological grade. The aim of this study is to evaluate the immunohistochemical expression of the SRSF1 protein in a series of astrocytic and non-astrocytic adult gliomas, emphasizing its potential use in the differential diagnosis of these neuropathological entities.Background: The aim of this study was to investigate the immunohistochemical expression and distribution of serine and arginine rich splicing factor 1 (SRSF1) in a series of 102 cases of both diffuse and circumscribed adult gliomas to establish the potential diagnostic role of this protein in the differential diagnosis of brain tumors. Methods: This retrospective immunohistochemical study included 42 glioblastoma cases, 21 oligodendrogliomas, 15 ependymomas, 15 pilocytic astrocytomas, 5 sub-ependymal giant cell astrocytoma and 4 pleomorphic xanthoastrocytomas. Results: Most glioblastoma (81%), oligodendroglioma (71%), sub-ependymal giant cell astrocytoma (80%) and pleomorphic xanthoastrocytoma (75%) cases showed strong SRSF1 immunoexpression, while no detectable staining was found in the majority of ependymomas (87% of cases) and pilocytic astrocytomas (67% of cases). Conclusions: The immunohistochemical expression of SRSF1 may be a promising diagnostic marker of astrocytomas and oligodendrogliomas and its increased expression might allow for excluding entities that often enter into differential diagnosis, such as ependymomas and pilocytic astrocytomas.